OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal hyperplasia
Designed to resist competition from endogenous ACTH by maximizing receptor residency time
OMS1620 demonstrates best-in-class efficacy in acute and chronic preclinical models of ACTH excess
Oxford, United Kingdom – 14th July 2025 – OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
This poster is the first public data disclosure related to OMS1620, a potential best-in-class MC2R antagonist currently in IND-enabling studies. MC2R is a GPCR for the adrenocorticotropic hormone (ACTH), a hormone released by the pituitary that triggers cortisol and androgen production. OMS1620 is being developed for diseases associated with ACTH excess, including congenital adrenal hyperplasia (CAH).
In classical CAH, patients are unable to produce cortisol and require exogenous glucocorticoid supplementation. In people without CAH, endogenous cortisol prevents ACTH upregulation but to achieve this in CAH patients, supraphysiological doses of glucocorticoids are usually required. This results in CAH patients having symptoms associated with ACTH over production (leading to androgen excess), side effects associated with glucocorticoid overdosing, or both.
ACTH surges in CAH can be many times above the upper limit of normal, last for multiple hours, and increase as patients try to downtitrate their glucocorticoid dose. OMS1620 has been exquisitely designed to maximize receptor residency time, making it highly resistant to competition from rising endogenous ACTH. This was demonstrated preclinically utilizing an acute ACTH challenge model in rats, an experiment meant to mimic the high levels of ACTH observed in CAH patients. Compounds with longer residence time were shown to have greater MC2 receptor inhibition. OMS1620 also led to improvement in body and adrenal weight in a chronic ACTH excess model, where Sprague Dawley rats were treated with ACTH via an osmotic mini-pump.
These results demonstrate OMS1620 is a potential best-in-class MC2 antagonist with the ideal compound properties to combat high ACTH surges that CAH patients can experience throughout the day. This can further support patients in achieving the ultimate treatment goal in CAH of androgen normalization whilst on physiological dose replacement of glucocorticoids.
Ros Deegan, Chief Executive Officer at OMass Therapeutics, commented: 'This compelling preclinical data validates our approach of optimizing our MC2 antagonists' residence time to deliver a best-in-class molecule in OMS1620. Our preclinical modelling suggests OMS1620's profile can further support patients as they try to achieve the ultimate treatment goal in CAH of normalizing androgen levels while on physiological doses of glucocorticoids. This underscores the potential of our MC2 program to transform outcomes for patients with CAH, a population with significant unmet need and we're excited to take the next step towards the clinic.'
The poster can be downloaded here.
-ENDS-
For further information, please contact:
OMass Therapeutics
Rosamond Deegan, Chief Executive OfficerEmail: ros.deegan@omass.com
ICR Healthcare (For media)
Namrata Taak / Ashley Tapp Email: omass@icrhealthcare.com
Thrust Strategic Communications (For IR)Renee LeckEmail: renee@thrustsc.com
About OMass Therapeutics
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes.
OdyssION™, OMass' unique drug discovery platform, comprises next-generation native mass spectrometry with novel biochemistry techniques and custom chemistry to interrogate not just a drug target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. This unique approach results in cell-system fidelity with cell-free precision.
OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead program is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-dependent Cushing syndrome. The focus of the program has been to increase receptor residency time to make OMass' antagonists resistant to competition by the endogenous ligand, thereby avoiding loss of efficacy in the face of rising adrenocorticotropic hormone (ACTH) levels due to reductions in glucocorticoid supplementation for CAH or progression of Cushing's Syndrome.
Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
To learn more, please visit www.omass.com. Follow us on LinkedIn.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Liverpool to submit new offer for star 'very keen' to join
Time is running out in the transfer window and Liverpool are still in the race to complete multiple deals. It's been a long summer, and the next two weeks are going to be even crazier than anything that has happened in the lead up to this. 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the away range TODAY LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Liverpool are far from being done in the transfer market. Richard Hughes wanted to rebuild Arne Slot's side this summer and the final pieces in the jigsaw are still yet to be secured. The first of those jigsaw pieces is Alexander Isak. He's been Liverpool's dream target for a long time and next week we should find a resolution to the saga that has been going on for the longest time. Liverpool may add another winger to the equation as well. Although it remains to be seen whether with such little time left they can find the right target. But the other key piece of the puzzle is Marc Guehi. 🔴 Like Isak, the Crystal Palace captain has long been on Liverpool's radar. In fact, the Reds have wanted to sign him since the beginning of the summer. Guehi has one year left on his contract and it's clear that he doesn't want to extend. He wants to leave the club. Whether it's in the next two weeks or next summer, the end result will be the same. So, it's in Palace's interest to make sure that he goes this summer. At least this way they won't lose him for nothing but they can actually get compensated for making Guehi into the player he is today. Liverpool have been working on a deal to do exactly that. They haven't yet succeeded but it looks like they are going to make another push for the Crystal Palace star.
Yahoo
2 hours ago
- Yahoo
UiPath (PATH) Launches Generative Extractions to Automate Complex Document Processing
UiPath Inc. (NYSE:PATH) is one of the UiPath Inc. (NYSE:PATH) is one of the best midcap AI stocks to buy right now. On August 1, 2025, UiPath announced the general availability of its new Generative Extractions capability for the Intelligent Document Processing (IXP) platform. The release enables users to automate the processing of unstructured and complex documents using generative AI. This includes parsing multi-table layouts, freeform text, embedded graphics, and other non-standard formats that traditional document automation tools often fail to handle effectively. The feature is now live in the U.S. and Europe, with public previews rolled out to customers in Canada, Australia, and Japan. This expansion marks a major step forward in UiPath's strategy to integrate large language model capabilities across its platform. By bringing generative document understanding to production environments, the company is positioning its platform not just for routine automation, but for high-complexity, high-volume enterprise workflows. With many global organizations still struggling to extract structured insights from PDFs, scans, and multi-modal documents, this feature directly addresses one of the most persistent gaps in automation. UiPath is a New York-based enterprise automation software company known for its robotic process automation (RPA) platform. UiPath is actively transitioning toward agentic automation, mixing deterministic RPA workflows with generative AI and AI agents. They've introduced tools like Agent Builder and launched the UiPath Platform for Agentic Automation, which orchestrates AI agents, robots, and humans into a unified intelligent system. While we acknowledge the potential of PATH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Thirsty Trump's Desperate Cold-Call About Nobel Peace Prize
President Donald Trump has stooped to cold calling Norwegian diplomats in his long-suffering bid to be awarded the country's coveted Noble Peace Prize. Norway's Finance Minister Jens Stoltenberg, the former NATO secretary-general, confirmed to Politico that Trump called him to discuss tariffs and economic cooperation between the two countries. 'It is true that President Trump called me a few days before his conversation with Prime Minister (Jonas Gahr) Støre. Several of the president's staff members also participated in the conversation, including Treasury Secretary Bessent and Trade Representative Greer,' said Stoltenberg. However, Norwegian newspaper Dagens Næringsliv reported on Thursday that the topic of the Nobel Peace Prize was also raised in their discussions, and it was the second such time that the topic was raised during a call. Stoltenberg added, 'I will not go into further detail about the content of the conversation.' In recent months, Trump has frequently proclaimed that he believes that he deserves a Nobel Peace Prize much more than the previous four presidents who have received the award—especially more than former President Barack Obama. '(Obama) didn't even know why the hell he got it, right? He still doesn't,' Trump told a Las Vegas audience last year during a campaign stop, The Independent reported. 'He got elected, and they announced he's getting the Nobel Prize. I got elected in a much bigger, better, crazier election, but they gave him the Nobel Prize.' In his second term, Trump has publicly ramped up the pressure to get his hands on the award and he has enlisted the help of his MAGA proxies to prove he is Nobel-worthy. Israel President Benjamin Netanyahu wrote a letter to the Norwegian Nobel Committee praising Trump for his role in negotiating the 2020 Abraham Accords. Laying it on thick, Netanyahu claimed that Trump was 'forging peace, as we speak, in one country in the region after another.' Armenia and Azerbaijan have also publicly come out in support of Trump winning the prize after a successful Aug. 8 summit at the White House saw the two countries walk away with a joint peace agreement to end a 37-year conflict, the Atlantic Council reported. 'I think President Trump deserved to have the Nobel Peace Prize,' Armenian Prime Minister Nikol Pashinyan said at the White House, 'and we will defend that, we will promote for that.' Now all eyes are on Trump's highly-anticipated meeting with Russian President Vladimir Putin in Alaska as he looks to finally put an end to Putin's full-scale invasion of Ukraine once and for all, something he promised to do on 'day one' of his presidency. A former aide in Trump's first term told The Hill 'there's no question the pressure's on' for the administration to secure the prize. 'Trump sees this prize as the ultimate capstone to how history will remember him,' they added. Yet even if Trump doesn't broker peace between Russian and Ukraine, MAGA pundit Geraldo Rivera declared that Trump deserves it anyway. 'If you have a president of the United States trying so hard... for peace, even if he's not totally successful, just the effort is so, it's so overt, it's so public, it's so aggressive. You know, he deserves recognition at least for that,' Rivera told Newsmax host Rob Finnerty on Wednesday. 'If he does end this war, Geraldo, can they deny him the Nobel Peace Prize?' Finnerty asked. 'Hell no,' Rivera said. 'I think that this and/or Gaza would put him on the fast track, and anyone to deny that, I think, would really be putting their partisan politics in front of their logic.' The Nobel Peace Prize will be awarded at a ceremony on Dec. 10, 2025, in Stockholm, Sweden. The Daily Beast has contacted White House representatives for comment on Trump's campaign push for the Nobel Peace Prize.
